Table 2.
Characteristics of Liver Transplant Eligible Sub-group of Patients With Unresectable Colorectal Liver Metastasis.
| Patient characteristics | Number of patients (n = 13) | |
|---|---|---|
| Male/Female | 8 (61.5%)/5 (38.5%) | |
| Median age with range (years) | 54 (29–62) | |
| Site of primary | Right Side | 1 (7.7%) |
| Left Side | 12 (92.3%) | |
| Timing of metastasis | Synchronous | 12 (92.3%) |
| Metachronous | 1 (7.7%) | |
| Histology - MDAC | 13 (100%) | |
| Molecular criteria | Ras mutated | 3 (23.1%) |
| Raf mutated | 0 | |
| MSI-H | 0 | |
| cT | T3 | 12 (92.3%) |
| T4 | 1 (7.7%) | |
| cN | N0 | 1 (7.7%) |
| N1 | 12 (92.3%) | |
| Median size of largest lesion with range (cm) | 3.60 (1.50–4.90) | |
| Surgery for the primary | 4 (30.8%) | |
| T4 and/or N2 status post neoajuvant therapy | 0 | |
| CEA at diagnosis of metastasis >80 ng/ml | 6 (46.2%) | |
| Increasing trend of CEA with chemotherapy | 0 | |
| Chemotherapy used | Oxaliplatin based | 12 (92.3%) |
| Irinotecan based | 1 (7.7%) | |
| Biological agent used | 6 (46.2%) | |
| Partial response to 6 months of chemotherapy | 13 (100%) | |
| Liver resectable post 6 months of chemotherapy | 0 | |
| Progression at 1 year post diagnosis of metastasis | 0 | |
| CEA at 1 year post diagnosis of metastasis >80 ng/ml | 1 (7.7%) | |
| Oslo score | 1 | 11 (84.6%) |
| 2 | 2 (15.4%) | |
| Organ of progression beyond 1 year of diagnosis of metastasis | Liver only | 10 (76.9%) |
| Liver and lung | 2 (15.4%) | |
| Liver, lung and periportal lymph nodes | 1 (7.7%) | |
Abbreviations: MDAC, Moderately-differentiated adenocarcinoma; MSI-H, Microsatellite Instability – High; cT, clinical tumour stage; cN, clinical nodal stage; CEA, Carcinoembryonic antigen.